3L18
 
 | |
1LU8
 | |
1S6X
 | | Solution structure of VSTx | | Descriptor: | KvAP CHANNEL | | Authors: | Jung, H.J, Eu, Y.J, Kim, J.I. | | Deposit date: | 2004-01-28 | | Release date: | 2005-03-22 | | Last modified: | 2022-03-02 | | Method: | SOLUTION NMR | | Cite: | Solution structure and lipid membrane partitioning of VSTx1, an inhibitor of the KvAP potassium channel.
Biochemistry, 44, 2005
|
|
3MWM
 | |
2JRV
 | | The third dimensional structure of mab198-bound pep.1 for autoimmune myasthenia gravis | | Descriptor: | PEPTIDE PEP.1 | | Authors: | Jung, H.H, Yi, H.J, Lee, S.K, Lee, J.Y, Jung, H.J, Yang, S.T, Eu, Y.-J, Im, S.-H, Kim, J.I. | | Deposit date: | 2007-06-29 | | Release date: | 2008-07-01 | | Last modified: | 2024-05-29 | | Method: | SOLUTION NMR | | Cite: | Structural analysis of immunotherapeutic peptides for autoimmune Myasthenia gravis
Biochemistry, 46, 2007
|
|
2JRW
 | | Solution structure of Cyclic extended Pep1(Cyc.ext.Pep.1) for autoimmune myasthenia gravis | | Descriptor: | Cyclic extended Pep.1 | | Authors: | Jung, H.H, Yi, H.J, Lee, S.K, Lee, J.Y, Jung, H.J, Yang, S.T, Eu, Y.-J, Im, S.-H, Kim, J.I. | | Deposit date: | 2007-06-29 | | Release date: | 2008-07-01 | | Last modified: | 2022-03-09 | | Method: | SOLUTION NMR | | Cite: | Structural analysis of immunotherapeutic peptides for autoimmune Myasthenia gravis
Biochemistry, 46, 2007
|
|
6ILQ
 | | Crystal structure of PPARgamma with compound BR101549 | | Descriptor: | Nuclear receptor coactivator 1, Peroxisome proliferator-activated receptor gamma, ethyl [2-butyl-6-oxo-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}-4-(propan-2-yl)-1,6-dihydropyrimidin-5-yl]acetate | | Authors: | Hong, E, Jang, T.H, Chin, J, Kim, K.H, Jung, W, Kim, S.H. | | Deposit date: | 2018-10-19 | | Release date: | 2019-09-11 | | Last modified: | 2023-11-22 | | Method: | X-RAY DIFFRACTION (2.408 Å) | | Cite: | Identification of BR101549 as a lead candidate of non-TZD PPAR gamma agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Bioorg.Med.Chem.Lett., 29, 2019
|
|
2NDB
 | |
6NYT
 | | Munc13-1 C2B-domain, calcium bound | | Descriptor: | CALCIUM ION, CHLORIDE ION, GLYCEROL, ... | | Authors: | Tomchick, D.R, Rizo, J, Machius, M, Lu, J. | | Deposit date: | 2019-02-12 | | Release date: | 2019-02-20 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.369 Å) | | Cite: | Munc13 C2B domain is an activity-dependent Ca2+ regulator of synaptic exocytosis.
Nat. Struct. Mol. Biol., 17, 2010
|
|
6NYC
 | | Munc13-1 C2B-domain, calcium free | | Descriptor: | 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, CHLORIDE ION, Munc13-1 | | Authors: | Tomchick, D.R, Rizo, J, Machius, M, Lu, J. | | Deposit date: | 2019-02-11 | | Release date: | 2019-02-20 | | Last modified: | 2023-10-11 | | Method: | X-RAY DIFFRACTION (1.893 Å) | | Cite: | Munc13 C2B domain is an activity-dependent Ca2+ regulator of synaptic exocytosis.
Nat. Struct. Mol. Biol., 17, 2010
|
|
